• Reducing Cardiovascular Risk in Patients with Renal Disease
  • CME

  • Reducing Cardiovascular Risk in Patients with Renal Disease

  • Author(s)/Faculty: Peter P. Toth, MD, PhD; Michael H. Davidson, MD, FACC, FACP, FNLA; John J. Russell, MD
    Source: Cardiology Today
    Type: Multimedia Articles/Items: 1
    Release Date: 8/4/2011 Expiration Date: 8/3/2012
    Credit Type: CME Number of Credit(s): 0.75
    Cost: Free Provider: Vindico Medical Education
  • Renal disease is a common and serious comorbidity for patients with cardiovascular disease. The SHARP Trial demonstrated that cholesterol lowering with a combination of simvastatin and ezetimibe in patients with renal disease resulted in a significant reduction in major arteriosclerotic events. This data provides important evidence for primary care and specialists alike that cholesterol lowering can reduce cardiovascular events in patients with renal disease, including those on dialysis. Leading clinicians will discuss the latest state of the science and how this will impact clinical care.

Sponsorship Statement: This continuing education activity is sponsored by .

Support Statement: This activity is supported by an educational grant from .

Target Audience: The intended audience for the activities is primary care physicians, internal medicine physicians, cardiologists, endocrinologists, nephrologists, and other health care professionals involved in the treatment of dyslipidemia in patients with chronic kidney disease.

Learning Objectives: At the conclusion of this activity participants should be able to:

 


  • Discuss the epidemiology of cardiovascular disease in chronic renal disease
  • Evaluate evidence-based medicine and clinical data on treatment regimens that result in a reduction in cardiovascular events in patients with renal disease
  • Implement practice strategies that reduce cardiovascular events in patients with renal disease, including those with renal insufficiency and renal failure

Course Chair:
Peter P. Toth, MD, PhD
Director of Preventive Cardiology
Sterling Rock Falls Clinic, Ltd.
Clinical Professor
University of Illinois School of Medicine
Sterling, IL

Faculty:
George L. Bakris, MD, FAHA, FASN
Professor of Medicine
Director, Hypertensive Diseases Unit
University of Chicago School of Medicine
Chicago, IL

Michael H. Davidson, MD, FACC, FACP, FNLA
Clinical Professor of Medicine
Director of Preventive Cardiology
The University of Chicago, Pritzker School of Medicine
Executive Medical Director
Radiant Research
Chicago, IL

John J. Russell, MD
Associate Director
Family Medicine Residency Program
Abington Memorial Hospital
Clinical associate Professor
Family and Community Medicine
Temple University School of Medicine
Abington, PA

External Reviewer:
Benjamin Ansell, MD

Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Vindico Medical Education designates this Enduring Material activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 4, 2011 to August 3, 2012.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the Pretest questions, watch and listen to the presentation, complete the Posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the Posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the Posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
Peter P. Toth, MD, PhD
Consulting Fees: Abbott Laboratories, AstraZeneca, Genzyme, Merck
Fees for Non-CME Services: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Pfizer, Takeda

George L. Bakris, MD, FAHA, FASN
Relationship: Grant/Research Support: Forest Labs CVRx, Novartis, PepsiCo
Consultant- Takeda, Abbott, Walgreen’s, CVRx, Johnson & Johnson, Medtronic, Servier
Boards:National Kidney Foundation

Michael H. Davidson, MD, FACC, FACP, FNLA
Speakers’ Bureau: Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Merck
Advisory Board/Consultant: Abbott Laboratories, Aegerion, Amgen, AstraZeneca, Atherotech, Daiichi-Sankyo, DTC MD, Esperion, GlaxoSmithKline, iMD (Intelligent Medical Decisions), Kinemed, LipoScience, Merck, Novo Nordisk, Roche, sanofi-aventis, Synarc, Takeda, Vindico Medical Education
Grant/Research: Abbott Laboratories, AstraZeneca, Daiichi-Sankyo, GlaxoSmithKline, Merck, Roche
Board of Directors: DTC MD, Omthera, Professional Evaluation, Inc. Medical Education Company, Sonogene

 

John J. Russell, MD
Fees for Non-CME Services: Sanofi-Pasteor

External reviewer reports the following relationship(s):

Benjamin Ansell, MD
Relationship: Fees for Non-CME Services: Pfizer, Roche; Consulting Fees: Pfizer Roche; Ownership Interest: Bruin Pharmaceuticals

Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2011. Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.